Literature DB >> 9647212

In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.

A Cerwenka1, L L Carter, J B Reome, S L Swain, R W Dutton.   

Abstract

Naive CD8 T cells can be polarized into effectors producing the type 1 cytokines IFN-gamma and IL-2 or the type 2 cytokines IL-4, IL-5, and IL-10, respectively. To study whether the polarized cytokine phenotype of the effectors is stable, we generated highly cytotoxic hemagglutinin (HA) peptide-specific CD8 Tc1 and Tc2 (cytotoxic CD8 T cells producing type 1 or type 2 cytokines) effectors from Clone-4 TCR-transgenic mice, which were adoptively transferred into syngeneic adult thymectomized irradiated and bone marrow-reconstituted recipients. The highly activated blast-size, CD25+ Tc1 and Tc2 effectors gave rise to homogeneous resting CD25- CD44(high) Ly6C(high) Ag-specific populations, which persisted for at least 13 wk after adoptive transfer. These memory CD8 T cells, recovered 13 wk after transfer of Tc1 or Tc2 effectors, still produced either the type 1 or type 2 cytokines, i.e., IFN-gamma, or IL-4 and IL-5, respectively, upon restimulation with APCs loaded with the HA peptide, but not in the absence of Ag. The amounts of IL-2 detected in the supernatants of Tc1 and Tc2 memory populations were comparable to that in memory CD4 cells, and both Tc1 and Tc2 memory cells became cytotoxic upon restimulation. Thus, cytokine-polarized CD8 memory T cells are a source of a variety of cytokines, which were classically considered helper cytokines, opening new perspectives on their function as regulatory cells in an immune response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9647212

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  Educating T cells: early events in the differentiation and commitment of cytokine-producing CD4+ and CD8+ T cells.

Authors:  A Kelso
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Regulatory functions of CD8+CD28- T cells in an autoimmune disease model.

Authors:  Nader Najafian; Tanuja Chitnis; Alan D Salama; Bing Zhu; Christina Benou; Xueli Yuan; Michael R Clarkson; Mohamed H Sayegh; Samia J Khoury
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

3.  Functional plasticity of an antigen-specific memory CD4 T cell population.

Authors:  Mojgan Ahmadzadeh; Donna L Farber
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

Review 4.  The role of gamma/delta T cells in immunity to infection and regulation of inflammation.

Authors:  H Kirk Ziegler
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 5.  Programming CD8+ T cells for effective immunotherapy.

Authors:  Christian S Hinrichs; Luca Gattinoni; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2006-04-17       Impact factor: 7.486

6.  Expression of complement receptor type 1 (CR1) on erythrocytes of paracoccidiodomycosis patients.

Authors:  J E Teixeira; R Martinez; L M Câmara; J E Barbosa
Journal:  Mycopathologia       Date:  2001       Impact factor: 2.574

7.  The MicroRNA miR-191 Supports T Cell Survival Following Common γ Chain Signaling.

Authors:  Erik Allen Lykken; Qi-Jing Li
Journal:  J Biol Chem       Date:  2016-09-15       Impact factor: 5.157

8.  The CD8+ memory T-cell state of readiness is actively maintained and reversible.

Authors:  Atef Allam; Dietrich B Conze; Maria Letizia Giardino Torchia; Ivana Munitic; Hideo Yagita; Ryan T Sowell; Amanda L Marzo; Jonathan D Ashwell
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

Review 9.  IL-4: an important cytokine in determining the fate of T cells.

Authors:  J L Silva-Filho; C Caruso-Neves; A A S Pinheiro
Journal:  Biophys Rev       Date:  2014-01-09

10.  Bacterial lipopolysaccharide both renders resistant mice susceptible to mercury-induced autoimmunity and exacerbates such autoimmunity in susceptible mice.

Authors:  M Abedi-Valugerdi; C Nilsson; A Zargari; F Gharibdoost; J W DePierre; M Hassan
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.